Tag Archives: NASDAQ:ZIOP

H.C. Wainwright Reaffirms Their Hold Rating on Ziopharm Oncology (ZIOP)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Hold rating on Ziopharm Oncology (ZIOP – Research Report). The company’s shares closed last Friday at $3.20. According to TipRanks.com, Ramakanth is a 5-star analyst with an average

What Made H.C. Wainwright Downgrade Ziopharm Oncology’s Stock?

In a report released today, Swayampakula Ramakanth from H.C. Wainwright downgraded Ziopharm Oncology (ZIOP – Research Report) to Hold. The company’s shares closed last Friday at $5.33, close to its 52-week high of $5.95. According to TipRanks.com, Ramakanth is a

Ziopharm Oncology (ZIOP) Receives a Buy from Raymond James

In a report issued on May 29, David Novak from Raymond James maintained a Buy rating on Ziopharm Oncology (ZIOP – Research Report). The company’s shares closed last Thursday at $2.74. According to TipRanks.com, Novak is a 3-star analyst with

H.C. Wainwright Reiterates Their Buy Rating on Ziopharm Oncology (ZIOP)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Ziopharm Oncology (ZIOP – Research Report) today and set a price target of $6.50. The company’s shares closed last Monday at $2.90, close to its 52-week low of $2.68. According

Raymond James Sticks to Its Buy Rating for Ziopharm Oncology (ZIOP)

In a report released today, David Novak from Raymond James maintained a Buy rating on Ziopharm Oncology (ZIOP – Research Report), with a price target of $5.50. The company’s shares closed last Monday at $3.14, close to its 52-week low

Ziopharm Oncology (ZIOP) Gets a Buy Rating from H.C. Wainwright

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Ziopharm Oncology (ZIOP – Research Report), with a price target of $6.50. The company’s shares closed last Monday at $5.21. According to TipRanks.com, Ramakanth has